 |
|
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
Jihyun An, Joo Hyun Sohn
Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online 2022 Dec 20 DOI: https://doi.org/10.3350/cmh.2022.0437
|
|
Citations to this article as recorded by
 Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Ho Soo Chun, Minjong Lee
Clinical and Molecular Hepatology.2023; 29(2): 377. CrossRef Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials
Zijie Jin, Yan Yuan, Chen Zheng, Shijian Liu, Hongbo Weng
Journal of Diabetes and its Complications.2023; 37(8): 108558. CrossRef A global survey of health care workers' awareness of non‐alcoholic fatty liver disease: The AwareNASH survey
Stan Driessen, Vivian D. de Jong, Koen C. van Son, Tatiana Klompenhouwer, Yann Colardelle, Marco Alings, Cristophe Moreno, Stefan D. Anker, Manuel Castro Cabezas, Adriaan G. Holleboom, Diederick E. Grobbee, Maarten E. Tushuizen
United European Gastroenterology Journal.2023; 11(7): 654. CrossRef Protein kinases: The key contributors in pathogenesis and treatment of nonalcoholic fatty liver disease-derived hepatocellular carcinoma
Rong Liu, Ming-Ping Qian, Ying-Yu Cui
Metabolism.2023; 147: 155665. CrossRef Iron depletion in “metabolic fatty liver syndromes”: a strong biological rationale with disappointing liver outcomes
Amedeo Lonardo
Exploration of Drug Science.2023; : 239. CrossRef Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan
Chin-Hsiao Tseng
Cancers.2023; 15(17): 4276. CrossRef
|